Key Management Personnel Shareholdings At 30 June 2023 the interests of the key management personnel in the ordinary shares in the Company were: Balance Ordinary Shares 30 June 2022 Acquired via Share Purchase Plan Acquired on Market Balance Ordinary Shares 30 June 2023 Dr Geoffrey Cumming 177,414 - - 177,414 Max Johnston 404,310 - - 404,310 Philip Powell 396,631 - 77,999 474,630 Dr Leearne Hinch 74,354 - - 74,354 Dr Gregory Rice - - 20,000 20,000 Mark Edwards - - - - Key Management Personnel Options At 30 June 2023 the interests of the key management personnel in options over ordinary shares in the Company were: Balance Options 30 June 2022 Acquired via Share Purchase Plan Granted as Remuneration Exercised Balance Options 30 June 2023 Dr Geoffrey Cumming 552,000 - - - 552,000 Max Johnston 500,000 - - - 500,000 Philip Powell 500,000 - - - 500,000 Dr Leearne Hinch 676,344 - 500,000 - 1,176,344 Dr Gregory Rice 150,000 - - - 150,000 Mark Edwards - - 150,000 - 150,000 Loans to Key Management Personnel There have been no loans to KMP’s during the financial year. Other Transactions with KMPs There have been no transactions with KMP’s during the financial year. In the prior year, after ceasing his role as Chief Scientific Officer on 17 August 2021, Dr Peter French received $42,400 under a consultancy agreement during the 30 June 2022 year, for strategic technology advice. Nothing was paid to Dr Peter French in the 2023 Financial Year. Voting and comments at the Company’s 2022 Annual General Meeting The Company received 99.22% of the vote in favour of its Remuneration Report for the 2022 financial year. The Company did not receive any specific feedback at the AGM on its remuneration policies. ** END OF REMUNERATION REPORT ** 33 Annual Report 2023
RkJQdWJsaXNoZXIy MjE2NDg3